
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc has demonstrated strong growth, delivering 72.5k next-generation sequencing (NGS) tests in the third quarter of 2024, reflecting a significant increase from previous quarters and year-over-year performance. The company's total revenue surged by 35.9% year-over-year, bolstered by a 30.6% increase in Genomics revenue and an even more impressive 44.6% growth in the Data & Other segment. Additionally, projections suggest that core Tempus can maintain a growth rate of approximately 30%, while improvements in EBITDA indicate a streamlined operational efficiency that further solidify a positive outlook for the company's financial trajectory.
Bears say
Tempus AI Inc faces a challenging environment, with potential declines in reimbursement rates and risks associated with losing market share in genomic testing, which could hinder revenue generation and dataset monetization. The company's flat year-over-year operating cash flow and a substantial debt load juxtaposed with its cash reserves raise concerns about its financial stability. Additionally, trading at an EV/revenue multiple of 8.3x for FY25, which is a discount compared to peers, highlights a lack of confidence in its future growth potential amid a competitive landscape.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares